Stockreport

Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans [Yahoo! Finance]

Inhibrx Biosciences, Inc.  (INBX) 
PDF rate, 5.5-month median progression-free survival and 87% disease control in heavily pretreated, unresectable metastatic colorectal cancer, with a manageable safety profi [Read more]